Quick Answer
Jasper Therapeutics, Inc. reported Cash and Equivalents of $28.69 million for fiscal year 2025.
Jasper Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $28.69M | -59.9% |
| 2024 | $71.64M | -17.6% |
| 2023 | $86.89M | +127.2% |
| 2022 | $38.25M | -54.8% |
| 2021 | $84.70M | +327.0% |
| 2020 | $19.84M | +1535.8% |
| 2019 | $1.21M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $50.90M | -45.0% | +28.8% |
| June 30, 2025 | $39.51M | -63.0% | -19.0% |
| March 31, 2025 | $48.80M | -58.8% | -31.9% |
| December 31, 2024 | $71.64M | -17.6% | -22.6% |
| September 30, 2024 | $92.50M | -10.9% | -13.4% |
| June 30, 2024 | $106.82M | -7.8% | -9.8% |
| March 31, 2024 | $118.47M | -8.4% | +36.4% |
| December 31, 2023 | $86.89M | +127.2% | -16.3% |
- Jasper Therapeutics, Inc. showed a decrease of -59.9% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2025 period, Jasper Therapeutics, Inc.’s cash and equivalents has grown by 2265.9% (from $1.21 million to $28.69 million).
- The most recent figure is from Jasper Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: